This 45-minute webinar is designed to provide healthcare professionals with the latest information on the risk of Japanese encephalitis for travellers to endemic areas. Presented by Professor Derek Evans; Fellow of the International Society of Travel Medicine and Royal Geographical Society; and Vice-Dean of the Faculty of Travel Medicine.
Valneva is a global independent vaccine company that covers the full value chain from discovery to commercialisation. Valneva is a fully integrated, commercial stage biotech company focused on developing innovative life-saving vaccines. The Company seeks financial returns through focused R&D investments in promising product candidates and growing financial contributions from commercial products, striving towards financial self-sustainability. Valneva’s portfolio includes two commercial vaccines for travelers: one for the prevention of Japanese encephalitis (IXIARO) and the second (DUKORAL) indicated for the prevention of cholera and, in some countries, prevention of diarrhea caused by ETEC.
